Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

CHK-336 was generally well tolerated in healthy volunteers who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics was well characterized with... | June 17, 2023

Related Keywords

Italy ,Milan ,Lombardia ,Noopur Liffick ,Andrew King ,Nasdaq ,Investor Relations Corporate Communications ,Exchange Commission ,Globenewswire Inc ,Novartis ,Chinook Therapeutics Inc ,Investor Relations Corporate Communications Media Contact ,First In Class Orally Administered ,Target Engagement ,First In Human Phase ,Maladaptive Tubular Epithelial Cells ,Chronic Kidney Diseases ,Common Initiating Mechanism ,Current Reports ,Annual Report ,Quarterly Reports ,Novartis Annual Report ,Vice President ,Investor Relations ,Corporate Communications ,Media Contact ,North Senior Manager ,Chinook Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Gas ,Igenerally ,Fell ,Ctolerated ,N ,Healthy ,Volunteers ,Who ,Eceived ,Single ,Doses ,P ,O ,00 ,G ,End ,Multiple , 0 ,Or ,4 ,Ayspharmacokinetics ,Haracterized Kdny Us16961l1061 ,